Clinical Trials Browser

INDUSTRY × Lymphoma, Mantle-Cell × Lenalidomide × Clear all

NCT04903197 2026-01-22

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1 Terminated

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01996865 2025-07-10

MAGNIFY

Phase 3 Completed

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04036448 2025-03-11

RevlimidPMS

LymphoidMyeloid

Lymphoma, Follicular, Myelodysplastic Syndromes, Recurrence, Lymphoma, Mantle-Cell

NCT03647124 2025-03-04

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Recurrence, Lymphoma, Mantle-Cell

NCT01744912 2022-05-11

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

241 enrolled 31 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT01021423 2019-11-19

RENEW

Phase 3 Terminated

9 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT00737529 2018-12-13

EMERGE

Phase 2 Completed

134 enrolled 26 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell